Hirotake Mizutani

This inventor holds 14 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 8 EPO patents. Top assignees: Millennium Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hirotake Mizutani. Retrieved from https://idiyas.com/inventor/hirotake-mizutani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 7)

% Patents Active = 92.9

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 8.2

ph-index = 5

Forward Citations = 109(Granted Patents)

Location History:

Arlington, MA (US) (2015 - 2020)
Cambridge, MA (US) (2011 - 2024)

Company Filing History:

12 out of 854

Millennium Pharmaceuticals Limited

patents

2 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2011-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054512 - Sting modulator compounds, and methods of making and using (2024-08-06),

2. 11542293 - Sting modulator compounds, and methods of making and using (2023-01-03),

3. 10780090 - Heteroaryl compounds useful as inhibitors of SUMO activating enzyme (2020-09-22),

4. 10335410 - Heteroaryl compounds useful as inhibitors of sumo activating enzyme (2019-07-02),

5. 9962386 - Heteroaryl compounds useful as inhibitors of SUMO activating enzyme (2018-05-08),

6. 9718788 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2017-08-01),

7. 9695154 - Heteroaryl inhibitors of sumo activating enzyme (2017-07-04),

8. 9683003 - Heteroaryl compounds useful as inhibitors of SUMO activating enzyme (2017-06-20),

9. 9458108 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2016-10-04),

10. 9150525 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2015-10-06),

11. 9139589 - Heteroaryls and uses thereof (2015-09-22),

12. 8933225 - Process for the synthesis of E1 activating enzyme inhibitors (2015-01-13),

13. 8481550 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2013-07-09),

14. 8008307 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2011-08-30),

Title: **Hirotake Mizutani: Innovator in STING Modulator Compounds**

Introduction

Hirotake Mizutani, based in Arlington, MA, is a prominent inventor with an impressive portfolio of 14 patents. His work primarily focuses on the development of innovative compounds that target vital biological pathways, demonstrating significant potential in the field of cancer treatment.

Latest Patents

One of Mizutani's latest patents is centered on STING modulator compounds, with methods for their synthesis and application. These modulators, designed to act as agonists, are crucial for the prophylaxis and treatment of cancer and other diseases related to STING signaling. The patent specifies a compound represented by a distinct formula, outlining the structure and pharmacological relevance of these modulators.

Career Highlights

Mizutani's career includes noteworthy contributions while working at prestigious companies such as Millennium Pharmaceuticals and Takeda Pharmaceutical Company Limited. His work at these firms has established him as a key player in pharmaceutical innovation, focusing on therapeutic strategies that harness the body's immune response to combat disease.

Collaborations

Throughout his professional journey, Mizutani has collaborated with esteemed colleagues including Steven P. Langston and Stepan Vyskocil. These collaborations have facilitated a robust exchange of ideas and fostered innovation within the sphere of pharmaceutical research and development.

Conclusion

Hirotake Mizutani's contributions to the field of medicine through his patents on STING modulators illustrate his commitment to advancing therapeutic techniques for cancer treatment and other diseases. His collaborative efforts and professional background in notable pharmaceutical companies further underscore his role as a significant inventor in the realm of biotechnology.

Profile summary based on public USPTO records.